Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
WATERTOWN, Mass., April 06, 2016 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15th Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.
A live audio webcast of the Needham presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase’s pipeline includes three antibiotic candidates: eravacycline, its late-stage clinical candidate, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected] Argot Partners Susan Kim 212-600-1902 [email protected]
